NEWS

Treatment of a big basilar artery

INR approaches to stroke and aneurysms

Balt International has announced receiving the CE mark for the Ballast ....

Balt International has announced receiving the CE mark for the Ballast .088 Long Sheath. The Ballast .088 Long sheath is indicated for the introduction of interventional devices into peripheral, coronary and neurovasculature. It is a class III medical device which is described as a guiding catheter and as an introducer sheath.The Ballast .088 will be commercially available in different lengths, from 80 cm, via 90 cm and up to a 100 cm long.This new generation sheath is designed with a braided reinforced proximal segment, an optimised progressively softer distal coil segment and a low-profile outer diameter to deliver the right balance between atraumatic navigation and proximal support.With this new Ballast .088 Long sheath, Balt International offers its premium sheath, designed to improve support and navigationPascal Girin, Balt International’s CEO stated, "The clearance of the Ballast .088 Long Sheath is a significant milestone in our global commercialisation efforts and a major step towards delivering a complete portfolio of innovative solutions"."The Ballast .088 Long Sheath represents an advance in technology for physicians around the world. It also is a fantastic representation of the capabilities of the new global Balt, with full R&D teams in both France and the USA developing physician inspired technologies to advance the care of patients with neurovascular diseases" commented Dave Ferrera, Senior VP of Global R&D and CTO of Balt USA.

AVMs, aneurysms and more

Right MCA aneurysm

Bilateral sigmoid sinuses stenosis

Follow the LINNC online LikedIn page!

Corindus Announces FDA Submission for Neurovascular Intervention Indicat...

Expansion of CorPath GRX into neurovascular intervention could mark first step in revolutionizing stroke treatmentWALTHAM, MA — February 14, 2019 — Corindus Vascular Robotics (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. CorPath GRX, the second generation robotic platform, received FDA clearance for percutaneous coronary intervention (PCI) in 2016 and peripheral vascular intervention (PVI) in 2018. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).

Comparison of pipeline embolization device sizing based on conventional...

An agreement study

Aneurysm treated with coils and flow diverter